Carisma Therapeutics Announces Clinical & Preclinical Updates at 37th Annual SITC Meeting Thumbnail Image Read more about Carisma Therapeutics Announces Clinical & Preclinical Updates at 37th Annual SITC Meeting
Affimed Provides Data Update from Two Phase 1/2A Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting Thumbnail Image Read more about Affimed Provides Data Update from Two Phase 1/2A Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting
BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno Modulatory Small Molecule Candidates Thumbnail Image Read more about BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno Modulatory Small Molecule Candidates
X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome Thumbnail Image Read more about X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy Thumbnail Image Read more about Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Thumbnail Image Read more about Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
Sesen Bio and Carisma Therapeutics Announce Merger Agreement Thumbnail Image Read more about Sesen Bio and Carisma Therapeutics Announce Merger Agreement
Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies Thumbnail Image Read more about Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma Thumbnail Image Read more about Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma
Apply to the Academic Clinical Trials Program Thumbnail Image Read more about Apply to the Academic Clinical Trials Program
